The demo attained equally its Main endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and excellent enhancements in liver fibrosis without having worsening of steatohepatitis, along with resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH when compared with placebo.1Lots of habits and W